Your browser doesn't support javascript.
loading
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries.
Yoo, Sang Gune K; Chung, Grace S; Bahendeka, Silver K; Sibai, Abla M; Damasceno, Albertino; Farzadfar, Farshad; Rohloff, Peter; Houehanou, Corine; Norov, Bolormaa; Karki, Khem B; Azangou-Khyavy, Mohammadreza; Marcus, Maja E; Aryal, Krishna K; Brant, Luisa C C; Theilmann, Michaela; Cífková, Renata; Lunet, Nuno; Gurung, Mongal S; Mwangi, Joseph Kibachio; Martins, Joao; Haghshenas, Rosa; Sturua, Lela; Vollmer, Sebastian; Bärnighausen, Till; Atun, Rifat; Sussman, Jeremy B; Singh, Kavita; Saeedi Moghaddam, Sahar; Guwatudde, David; Geldsetzer, Pascal; Manne-Goehler, Jennifer; Huffman, Mark D; Davies, Justine I; Flood, David.
Afiliação
  • Yoo SGK; Cardiovascular Division, Department of Internal Medicine, Washington University in St Louis, St Louis, Missouri.
  • Chung GS; Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Bahendeka SK; Department of Internal Medicine, MKPGMS Uganda Martyrs University, Kampala, Uganda.
  • Sibai AM; St Francis Hospital, Nsambya, Kampala, Uganda.
  • Damasceno A; Epidemiology and Population Health Department, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
  • Farzadfar F; Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
  • Rohloff P; Nucleo de Investigaçao, Departamento de Medicina, Hospital Central do Maputo, Maputo, Mozambique.
  • Houehanou C; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Norov B; Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala.
  • Karki KB; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts.
  • Azangou-Khyavy M; Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
  • Marcus ME; Nutrition Department, National Center for Public Health, Ulaanbaatar, Mongolia.
  • Aryal KK; Department of Community Medicine and Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.
  • Brant LCC; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Theilmann M; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Cífková R; Bergen Centre for Ethics and Priority Setting in Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Lunet N; Public Health Promotion and Development Organization, Kathmandu, Nepal.
  • Gurung MS; Serviço de Cardiologia e Cirurgia Cardiovascular, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Mwangi JK; Departamento de Clínica Médica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Martins J; Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany.
  • Haghshenas R; Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany.
  • Sturua L; Center for Cardiovascular Prevention, First Faculty of Medicine, and Thomayer University Hospital, Charles University in Prague, Prague, Czechia.
  • Vollmer S; Department of Medicine II, First Faculty of Medicine, Charles University in Prague, Prague, Czechia.
  • Bärnighausen T; Department of Public Health and Forensic Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Atun R; EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal.
  • Sussman JB; Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.
  • Singh K; Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan.
  • Saeedi Moghaddam S; Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya.
  • Guwatudde D; Faculty of Medicine, The Institute of Global Health, University of Geneva, Geneva, Switzerland.
  • Geldsetzer P; Faculty of Medicine and Health Sciences, National University of East Timor, Dili, Timor-Leste.
  • Manne-Goehler J; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Huffman MD; Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia.
  • Davies JI; Public Health Department, Petre Shotadze Tbilisi Medical Academy, Tbilisi, Georgia.
  • Flood D; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
JAMA ; 330(8): 715-724, 2023 08 22.
Article em En | MEDLINE | ID: mdl-37606674
ABSTRACT
Importance Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD.

Objective:

To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. Design, Setting, and

Participants:

Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. Exposures Countries' per capita income levels and world region; individuals' socioeconomic demographics. Main Outcomes and

Measures:

Self-reported use of aspirin for secondary prevention of CVD.

Results:

The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. Conclusion and Relevance Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Aspirina / Prevenção Secundária Tipo de estudo: Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Aspirina / Prevenção Secundária Tipo de estudo: Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2023 Tipo de documento: Article